Key points are not available for this paper at this time.
Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Matthew R. Smith
Fred Saad
Simon Chowdhury
New England Journal of Medicine
Harvard University
University of California, San Francisco
Massachusetts General Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Smith et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69dd258403ecda3005e52d50 — DOI: https://doi.org/10.1056/nejmoa1715546